Bicara Therapeutics Inc. Common Stock
BCAX | NASDAQ
$22.01
-$0.63 (-2.78%)
At close: Sep 21, 2026, 4:00 PM ET
$22.01
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Key Executives
| Name | Position |
|---|---|
| Claire Mazumdar Clemon | Chief Executive Officer & Director |
| Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary |
| Pauline Dufresne | Chief People Officer |
| Ryan Cohlhepp | President, Chief Operating Officer & Director |
| Angela Windt | Vice President & Head of Regulatory Affairs |
| Ivan Hyep | CFO & Treasurer |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs |
| Jenna Cohen | Chief Corporate Affairs Officer |
| Jennifer Larson | CFO, Treasurer & Principal Accounting Officer |
| Rachel Frank | Vice President of Investor Relations and Corporate Communications |
| Rachel Salazar | SVP of R&D Strategy and Operations |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 3 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
Bicara Therapeutics Inc. Common Stock
| Country | United States |
| IPO Date | Sep 12, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Claire Mazumdar Clemon |
Contact Details
116 Huntington Avenue Boston,
Massachusetts 02116 United States
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002023658 |
| CUSIP Number | 055477103 |
| ISIN Number | US0554771032 |
| SIC Code | 2834 |
Recent News
- 1 month ago / seekingalpha.comBicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
- 1 month ago / benzinga.comBicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
- 1 month ago / seekingalpha.comBicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
- 1 month ago / marketbeat.comBicara Therapeutics Q2 Earnings Call Highlights
- 2 months ago / globenewswire.comBicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
- 2 months ago / globenewswire.comBicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
- 4 months ago / seekingalpha.comBicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
- 4 months ago / marketbeat.comBicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
- 4 months ago / globenewswire.comFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
- 4 months ago / marketbeat.comBicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Add to Watchlist
Select watchlists to add or remove BCAX